Juvenile RA: Fewer disease flares with Adalimumab (TNF Antibody)
Adalimumab with or without Methotrexate in Juvenile Rheumatoid ArthritisN Engl J Med. 2008 Aug 21;359(8):810-20
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
This was a three part study designed to assess the effectiveness of Adalimumab, a fully human monoclonal anti-TNF antibody, in the treatment of juvenile rheumatoid arthritis. The study consisted of an open-label lead-in phase (where patients were stratified according to methotrexate use), a double-blind withdrawal phase (following the 16 week lead-in phase, patients with an ACR Pedi 30 response we...
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.Continue